NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Adagene Inc. ADAG
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.7M
▲ 7332.8% vs FY2024
EPS · FY25
$-0.30
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-41.0%
Net margin · FY25
-229.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.7M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 230 cents on every revenue dollar this year.
Per share
USD -0.30
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-41.0%
Return on equity, FY2025
ROE
Operating margin-279.5%
Net margin-229.6%
Return on assets-21.0%
Each USD of equity lost 41 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+61.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−6.2%
+61.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 78.3M
total assets, end of FY2025
Total assetsUSD 78.3M
EquityUSD 35.3M
CashUSD 74.5M
Gross debtUSD 1.8M
Net debtUSD -72.7M
Current ratio3.07×
The company holds more cash than debt.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
−0.0
−0.0
0.0
0.0
0.0
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.30
−0.59
−0.35
−1.48
−1.46
−2.67
−1.10
−0.94
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−41.0
−55.2
−24.7
−66.7
−217.9
·
·
·
Shares out B
0.06
0.06
0.06
0.05
0.05
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed